ArticleNature communications2022
TPGS-based and S-thanatin functionalized nanorods for overcoming drug resistance in Klebsiella pneumonia.
Article in Nature communications, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 48 citations in OpenAlex.
- "Alkaline-Hammer Strategy" Breaks Acidic and Stromal Barriers to Induce Alkaliptosis and Enhance Immunotherapy in Pancreatic Cancer.Angewandte Chemie (International ed. in English) · 2026Article
- In Silico Rational Design of Novel 1,3,4-Oxadiazole Thioether Derivatives for the Discovery of Xanthomonas oryzae Inhibitors.Chemistry & biodiversity · 2026Article
- Design and evaluation of a bifunctional fusion polypeptide for targeted delivery of tigecycline against drug-resistant Klebsiella pneumoniae.Journal of nanobiotechnology · 2026Article
- Biomimetic metal-drug coordination nanoplatform to counteract drug resistance in Pseudomonas aeruginosa via energy disruption.Nature communications · 2026Article
- Chitosan-dextran sulfate nanocapsules for enhanced tigecycline efficacy against non-typhoidal Salmonella enterica.Scientific reports · 2026Article
- Overcoming multidrug resistance: antimicrobial peptides as a next-generation therapeutic strategy.Frontiers in cellular and infection microbiology · 2026Review
- Combating Gram-negative infections: The role of antimicrobial peptides and nanotechnology in overcoming antibiotic resistance.Materials today. Bio · 2025Review
- Exogenous adenosine counteracts tigecycline resistance inMicrobiology spectrum · 2025Article
- Activity-based protein profiling guided new target identification of quinazoline derivatives for expediting bactericide discovery: Activity-based protein profiling derived new target discovery of antibacterial quinazolines.Journal of advanced research · 2025Article
- Self-assembled and intestine-targeting florfenicol nano-micelles effectively inhibit drug-resistantJournal of pharmaceutical analysis · 2025Article
- Single-Atom Cu Anchored on Carbon Nitride as a Bifunctional Glucose Oxidase and Peroxidase Nanozyme for Antibacterial Therapy.ACS nano · 2025Article
- A Comprehensive Overview ofInfection and drug resistance · 2025Review
- Transmission Dynamics and Novel Treatments of High Risk Carbapenem-ResistantPharmaceuticals (Basel, Switzerland) · 2024Review
- Biomimetic Metal-Organic Framework Gated Nanoplatform for Sonodynamic Therapy against Extensively Drug Resistant Bacterial Lung Infection.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
- Engineering Photothermal Catalytic COAdvanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
- Repurposing harmaline as a novel approach to reverse tmexCD1-toprJ1-mediated tigecycline resistance against klebsiella pneumoniae infections.Microbial cell factories · 2024Article
- Injectable Nano-Micro Composites with Anti-bacterial and Osteogenic Capabilities for Minimally Invasive Treatment of Osteomyelitis.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
- Vitamin E TPGS-Based Nanomedicine, Nanotheranostics, and Targeted Drug Delivery: Past, Present, and Future.Pharmaceutics · 2023Review
- Recent advances of cell membrane-coated nanoparticles for therapy of bacterial infection.Frontiers in microbiology · 2023Review
- Epidemiological characteristics ofFrontiers in microbiology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tigecycline is regarded as the last line of defense to combat multidrug-resistant Klebsiella pneumoniae. However, increasing utilization has led to rising drug resistance and treatment failure. Here, we design a D-alpha tocopheryl polyethylene glycol succinate-modified and S-thanatin peptide-functionalized nanorods based on calcium phosphate nanoparticles for tigecycline delivery and pneumonia therapy caused by tigecycline-resistant Klebsiella pneumoniae. After incubation with bacteria, the fabricated nanorods can enhance tigecycline accumulation in bacteria via the inhibitory effect on efflux pumps exerted by D-alpha tocopheryl polyethylene glycol succinate and the targeting capacity of S-thanatin to bacteria. The synergistic antibacterial capacity between S-thanatin and tigecycline further enhances the antibacterial activity of nanorods, thus overcoming the tigecycline resistance of Klebsiella pneumoniae. After intravenous injection, nanorods significantly reduces the counts of white blood cells and neutrophils, decreases bacterial colonies, and ameliorates neutrophil infiltration events, thereby largely increasing the survival rate of mice with pneumonia. These findings may provide a therapeutic strategy for infections caused by drug-resistant bacteria.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.